Background The long-term prognosis and serial angiographic follow-up beyond 10 years in patients who underwent coronary artery bypass grafting (CABG) have not been fully studied in Japan.
n 1962, Sabiston performed the first case of coronary artery bypass grafting (CABG) to the right coronary artery, using a reversed segment of saphenous vein, but the patient died of a postoperative accident. 1 Green et al used a left internal thoracic artery (LITA), and anastomosed its distal end to the left anterior descending coronary artery (LAD). 2 Favalore established the use of saphenous vein grafts (SVGs) for multivessel bypass. 3 In Japan, CABG is also widely performed; for example, since 1975 in Juntendo University School of Medicine. However, the long-term prognosis and serial angiographic follow-up beyond 10 years in patients who have undergone CABG have not been fully studied in Japan, so we investigated those who underwent CABG before 1992 and performed a clinical and serial angiographic follow-up.
Methods

Study Patients
We selected 71 patients who underwent CABG before 1992 and were willing to undergo the long-term clinical and angiographic follow-up. All patients underwent CABG in Juntendo University School of Medicine and were followed in Juntendo Urayasu hospital. Of these patients, 30 had a SVG only, and the remaining 41 had a LITA to LAD graft. We investigated clinical course and prognosis, and coronary risk factors of the patients with SVG alone (SVG group) and compared them with the patients with LITA (LITA group). All patients in the SVG group had a SVG to LAD graft, whereas in the LITA group, all patients had LITA to LAD and SVG to the other coronary vessels. The major adverse cardiac events (MACE) were defined as cardiac death, Q-wave or nonQ-wave myocardial infarction, and congestive heart failure. Hyperlipidemia was defined as requiring antihyperlipidemic drugs or a total cholesterol (TC) >220 mg/dl. Diabetes mellitus (DM) was defined as a requirement for therapy with medication and/or with a fasting blood sugar (FBS) of more than 140 mg/dl, and/or a blood sugar >200 mg/dl on occasion. Baseline clinical and procedural data were collected for all patients.
Coronary Angiography
The patients gave informed consent to undergo serial angiography at 1, 5 and 10 years after CABG, regardless of their symptoms. The films were of good quality and the repeat studies were always compared with the baseline coronary arteriograms. The films were each read by 2 angiographers working together to reach a consensus. Stenosis of the coronary arteries and grafts was defined as the linear percentage of narrowing of the diameter of the vessel compared with the diameter of the nearest normal segment. In this study, patent graft meant widely patent or stenosis less than 99% narrowing. Percutaneous coronary intervention (PCI) to the SVG and native coronary arteries 
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were performed after CABG and procedural success was defined as a reduction in the degree of stenosis to less than 25% on quantitative angiography. If there were recurrent symptoms, coronary angiography was performed immediately and even if there were no symptoms, follow-up coronary angiography was performed 6 months later. Restenosis was defined as narrowing of 50% or more of the luminal diameter.
Statistical Analysis
Values are expressed as mean ± standard deviation. Differences in baseline characteristics between the 2 groups were evaluated by Fisher's exact test. The Student's t-test was used for continuous variables. Rates of graft patency and MACE-free survival rate were analyzed by Kaplan-Meier methods. Statistical comparisons were made using the log rank or generalized Wilcoxon methods. Probability values <0.05 were considered statistically significant.
Results
Patient Characteristics
The baseline characteristics of the 71 study patients (LITA group: 41 cases; SVG group: 30 cases) are shown in Table 1 . There were 63 men and 8 women, and the mean age was 55.9±9.0 years. The mean follow-up was 12.4 years. There were no differences in the baseline clinical characteristics between the 2 groups. We measured TC concentration, FBS, and body mass index (BMI) prior to CABG and in the postoperative follow-up period. The serum concentration of TC decreased from 225.7±65.5 to 182.1±37.5 mg/dl (p<0.01), but FBS and BMI did not change significantly in the interval. There were no differences in the TC concentration or BMI between the 2 groups. Although the number of DM patients was 19 (26.8%) in our study, only 2 used insulin, so the degree of DM control was very good. After CABG, almost all patients (97.2%) received aspirin; 2 did not because of contraindications. Angiotensin-converting-enzyme inhibitor (ACEI) and statins were given in 32 (45.1%) and 42 (59.2%) patients, respectively. There were no differences in medication status between the 2 groups. All patients had good control of hypertension.
Outcome of Clinical Follow-up
Of the 18 patients who died during follow-up, the cause of death was cardiac in 8, and noncardiac in 10 patients ( Table 2 ). In the SVG group, 3 and 2 patients died of sudden death and congestive heart failure, respectively. Six patients died of malignancy, which was the most common cause of death after CABG. The 1-, 5-, 10-, and 15-year MACE-free rates were 97.6%, 95.1%, 87.8%, and 75.0%, respectively, in the LITA group, compared with 96.7%, 90.0%, 70.0%, and 53.9% in the SVG group, demonstrating a higher cumulative MACE-free rate for the LITA group over the 15 years (p<0.05) ( Fig 1A) .
We investigated the effects of an ejection fraction (EF) ≥0.40 at the time of operation compared with EF <0.40 on the MACE-free rate. In the patients with an EF ≥0.40, there was a significant difference in favor of the LITA group compared with the SVG group (p<0.05) ( Fig 1B) , but no significant difference between the 2 groups for patients with an EF <0.40, (Fig 1C) . The presence of DM or hyperlipidemia did not affect the MACE-free rate.
Graft Patency Rates
Kaplan-Meier analysis showed that the 1-, 5-, 10-, and 15-year patency rates were 97.6%, 97.6%, 95.0%, and 95.0%, respectively, in the LITA group, compared with 88.0%, 83.4%, 73.6%, and 63.5% in the SVG group, demonstrating a higher cumulative patency of the LITA grafts (Fig 2A) . SVG patency rates were lower in the presence of hyperlipidemia (p<0.05) ( Fig 2B) , but did not differ significantly according to the presence or absence of DM ( Fig 2C) or smoking. We examined the SVG patency rate in patients with hyperlipidemia whose TC concentration was consistently lowered to <180 mg/dl with statin and diet therapies in the follow-up period after CABG. On average the 14.3-year patency rate was significantly higher in patents whose TC concentration was lowered than in those with uncontrolled cholesterol (p<0.05) (Fig 3) .
PCI After CABG
PCI was performed for 14 lesions and 10 lesions of the SVG and native coronary arteries, respectively, in an average of 13.1 years after CABG. The type of PCI was plain old balloon angioplasty (POBA) in 9 lesions and 7 lesions of the SVG and native coronary arteries, respectively, and stenting was performed in 5 lesions and 3 lesions, respectively. Successful procedural rates were high and similar for the SVG and native coronary arteries. The restenosis rates of the SVG were 66.7% and 40.0% for POBA and stenting, respectively. The results of PCI in the SVG tended to be less favorable than those in native coronary artery, with rates of restenosis exceeding 50% (Table 3) .
Restenosis rates for PCI were unrelated to TC concentrations or DM.
Discussion
The graft patency rate is higher for an internal thoracic artery (ITA) graft than for the SVG, 4,5 and the use of ITA grafts improves postoperative survival and cardiac eventfree rates. 6 However, few long-term serial angiographic follow-up studies after CABG have been conducted in Japan. The present study describes long-term survival rates and the natural course of disease in patients who underwent CABG for standard indications between 1977 and 1992. Currently, high-frequency transthoracic Doppler echocardiography can used for noninvasive diagnosis of LITA graft stenosis, but the detection rate is only 81%. 7 The diameters of the coronary arteries determined by electronbeam computed tomography are equal to the corresponding quantitative coronary angiography measurements, but it is an unrealistic technique in routine practice because the need for intricate callibration. 8 Therefore, in the present study we used coronary angiography, which is an established examination technique.
Beyond 10 years after CABG, SVGs show histologic evidence of atherosclerosis, 9 whereas arterial grafts are Fig 3. Relation between the patency rate of SVG and the reduction of total cholesterol (TC). In patients whose TC was consistently lower than 180 mg/dl, the SVG patency rate was significantly better than that in patients whose TC was more than 180 mg/dl. highly resistant to atherosclerosis. Treating patients with platelet inhibitors and statins seem to increase SVG patency rates and lower the rate of developing atherosclerosis, 10, 11 so postoperatively, all current patients are treated with aspirin unless contraindicated. But, at the time that patients in the present study underwent CABG, the efficacy of cholesterol-lowering treatment in delaying the progression of atherosclerosis in the SVG was not documented nor were statins being used yet. For this reason, we started prescribing statins for many of the patients with long-standing hyperlipidemia after CABG and most had good control of the hyperlipidemia. Our study demonstrates that aggressive cholesterol-lowering therapy with statins is effective for long-term patency in the SVG, even if therapy is not started immediately postoperative. Currently, very little data exist that compare loss of graft patency between CABG patients with and without DM. In the present study, 15 years after surgery there was a tendency for a difference in the SVG patency rate between DM and nonDM patients. A continuous follow-up study is necessary to clarify this finding. In a Western study, the LITA patency rate at 10 years after CABG was about 95%, which is similar to our result. 4, 5 On the other hand, the SVG patency rate at 10 years after CAGB has been reported as 50-60%, 12 which compared unfavorably with the result from study. We assume the following reasons for these differences between the studies. First, there may be a racial difference. Second, the patients in the Western studies did not necessarily undergo routine follow-up angiography, so their estimates of patency may be overestimated. Last although comparisons of the results from institutions with different postoperative management protocols are difficult, the patients in our study had good control of hyperlipidemia.
Table 3 Angiographic Restenosis of Percutaneous Coronary Intervention in Saphenous Vein Grafts and Native Coronary Arteries
The MACE-free rate was higher in the LITA group than in the SVG group, which we attributed to the high patency rate of the LITA graft. However, in patients with EF <0.4, a LITA graft for CABG did not appear to have a favorable result on the MACE-free survival rate, despite the good patency. A Japanese study that evaluated the benefit of both and single ITA for multivessel disease demonstrated that both grafts significantly improved the cardiac event-free survival rate in patients with EF >0.4, but there was no additional benefit in long-term survival for patients EF ≤0.4. 13 Our data also suggest that LITA grafts may not reduce cardiac events, such as sudden death caused by cardiac dysfunction, in patients with EF <0.4. ACEI andadrenergic-receptor antagonists are the standard treatment for patients with heart failure and systolic left-ventricular dysfunction [14] [15] [16] and in the present patients with systolic dysfunction, the efficacy of LITA was limited, so we actively prescribe ACEI and -blocker therapy for them.
DM increases the progression of coronary artery disease, 17 although in our study, the presence of DM or hyperlipidemia did not have an affect on the MACE-free rate. Hypertension is an independent predictor of outcome in patients with DM and previous trials have demonstrated the absolute importance of tight blood pressure control. 18, 19 We aggressively controlled blood pressure with antihypertensive drugs such as ACEI and calcium antagonists, and our findings suggest that there was no difference in the MACEfree rate between DM and nonDM patients. Trials have demonstrated the benefits of aggressive cholesterol-lowering therapy for most patients with coronary artery disease, even when the TC concentrations are within a normal range. 20, 21 Statins are known to ameliorate endothelial dysfunction, stabilize atherosclerotic plaque, and modify the inflammatory response and thrombus formation, 22 but the results of our study do not clarify if the effect of the therapy was directly protective or the result of the cholesterol-lowering effects of statins. The goal of our cholesterol-lowering therapy was TC <180 mg/dl, and its efficacy may be reflected in the SVG patency rate and MACE-free rate. The present patients also underwent nonpharmacological management such as counseling for weight loss, smoking cessation, increased physical activity, and reduced alcohol consumption. BMI did not significantly differ between the measurement intervals, but the number of patients who continue to smoke after CABG was reduced to only 4. Although we did not investigate the progression of disease in the nongrafted arteries, we speculate that good control of coronary risk factors would inhibit the progression of disease not only in the SVG, but also in the native coronary arteries.
In the comparison of POBA, in the SVG it was associated with increased rates of procedural complications and restenosis than the in native coronary arteries. Although stenting in the SVG resulted in a superior reduction in MACE, as compared with POBA, there was no significant benefit in the rate of angiographic restenosis. 23 The results of PCI in SVG have been disappointing, and management of SVG disease is problematic. Although stenting in the SVG resulted in a superior reduction of restenosis rates, there was no significant difference in the rate of restenosis in the SVG between POBA and stenting, which demonstrates the importance of preventing progression of atherosclerotic disease in the SVG. In addition, lipid-lowering therapy is important for SVG patency.
Finally, because malignancy was identified as the most common cause of death in this study, it is necessary to follow-up patients at regular intervals after CABG.
Study Limitations
More than 10 years ago, the introduction of percutaneous transluminal coronary angioplasty was an important advancement in the treatment of ischemic heart disease and its role in the treatment of single-vessel coronary artery disease has been well established. 24, 25 However, coronary stenting was not as widely used at that time. Currently, patients with 1-or 2-vessel disease of the LAD with a proximal lesion undergo CABG, and the concomitant use of the gastroepiploic artery with both ITAs results in low mortality and a low incidence of myocardial infarction and repeat intervention at follow-up. 26 It is suggested that complete revascularization using arterial grafts is important; however, many of the present patients underwent CABG using an LITA graft only to the LAD or a SVG alone. In the earlier part of this study, more SVGs were used than LITA grafts and thus, the background of the patients differed from those in the present time. Our findings cannot be generalized to every post CABG surgery patient, because the study subjects were pre-selected for their willingness to participate in long-term follow-up. It is also possible that the present results are biased favorably, because the patients who were eligible for this study were carefully controlled for coronary risk factors and might have had a better angiographic outcome. On the other hand, angiography was performed routinely, even for nonsymptomatic patients, allowing us to determine the status of grafts and native coronary arteries post CABG. 
Conclusion
The patency rate was higher in LITA grafts than in SVG and the event-free survival rate was higher when using an arterial graft than a venous graft, especially in long-term follow-up beyond 10 years. In patients with an EF <0.40, however, LITA did not prove of great benefit to the MACEfree rate. We recommend that ACEI and -blocker therapy should be routine. The results of PCI in SVG were not favorable, as the restenosis rate was high. Because hyperlipidemia was related to the patency of SVG, cholesterollowering therapy, such as statins and diet therapy, had a beneficial effect on the patency of SVG in patients with hyperlipidemia. Thus, medical treatment might be an important factor for the management of patients beyond 10 years after CABG.
